Christopher Downs - 19 Nov 2021 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: Chief Financial Officer
Issuer ticker: CNSP
Reported as of: 19 Nov 2021
Net transaction value: +$5,192
SEC form: 4
Accepted by SEC: 22 Nov 2021, 07:47:56 UTC
Next SEC filing: 07 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Christopher Downs

Key filing fact

Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 22 Nov 2021.

Key facts

This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Nov 2021, 07:47.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$5,192.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNSP transaction

Common Stock

Purchase

Transaction value: $5,192
Shares: +4,500
Change %: +3.2%
Price: $1.15
Shares after: 146,500
Date: 19 Nov 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades at prices ranging from $1.14 to $1.155. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.